Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)

NCT ID: NCT03035344

Last Updated: 2017-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of the intermediate metabolism in children diagnosed with ALL compared to healthy matched controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary cause of this study is to investigate the changes that ALL may cause to the metabolome of pediatric patients, in order to better understand its mechanism of action and target metabolic pathways for potential therapies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphoblastic Leukemia, Pediatric Metabolism Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALL paediatric patients

Metabolome study in children diagnosed with ALL after bone marrow biopsy

Metabolome study

Intervention Type OTHER

Metabolome study in ALL patients compared to healthy controls

Healthy matched controls

Metabolome study in healthy children matched for gender and age with the patients group

Metabolome study

Intervention Type OTHER

Metabolome study in ALL patients compared to healthy controls

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metabolome study

Metabolome study in ALL patients compared to healthy controls

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Population description: Patients are recruited from the Pediatric Hematology/Oncology Department of Aristotle University of Thessaloniki (AHEPA hospital) and from the Pediatric Hematology/ Oncology Department of Ippokration Hospital, that host all children diagnosed with ALL in nothern Greece. Matched controls are recruited from outpatient clinic of the 2nd and 4th Pediatric Department of Aristotle University of Thessaloniki.
* Sampling method: Non-probability sample
Minimum Eligible Age

1 Month

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aristotle University Of Thessaloniki

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maria T. Papadopoulou

Principal investigator, MD, PhD candidate

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Athanassios Evangeliou, Prof

Role: STUDY_CHAIR

Aristotle University Of Thessaloniki

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aristotle University of Thessaloniki

Thessaloniki, , Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maria T. Papadopoulou, MD

Role: CONTACT

6932343539

Athanassios Evangeliou, Prof

Role: CONTACT

00302313323916

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maria T. Papadopoulou, MD

Role: primary

+306932343539

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHILDHOOD ALL METABOLOMICS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.